Literature DB >> 12381946

Prospective evaluation of an in-center daily hemodialysis program: results of two years of treatment.

Mauro B André1, Simone M Rembold, Claudia M Pereira, Jocemir R Lugon.   

Abstract

Short duration daily hemodialysis (DHD) emerges as a well-tolerated alternative to standard hemodialysis (SHD). In this prospective study 5 patients in SHD were recruited to participate in an in-center DHD program. The SHD consisted of 3 sessions of 4 h each per week. Nonproportional mixture machines without an ultrafiltration control device and low flow dialyzers were used. For DHD, dialysis equipment and procedures were kept the same. Dialysis sessions, however, began at 6 p.m. (from Monday to Saturday) and lasted 2 h. Data from the last 6 months on SHD of the same patients were compared with the ones from each semester on DHD. Bone biopsy was performed at start and at the end of the 2-year study period. Hypotensive episodes, hypertensive crisis, cramps and headaches became 7-10 times less frequent in daily dialysis. A significant fractional increase ( approximately 12%) was seen in mean values for hematocrit. Predialysis urea levels as well as predialysis creatinine levels declined significantly. Also lower during the daily dialysis period were the mean values for both phosphorus and CaxP product. Significant increases were found in serum bicarbonate, albumin and in dry weight. The frequency of mean blood pressure >/=110 mm Hg on arrival for dialysis was significantly lower in every semester on daily hemodialysis. A significant twofold improvement in quality of life scoring was observed. Finally, daily hemodialysis also seemed to be beneficial to low turnover bone disease and bone aluminum deposition. These beneficial effects occurred despite of an increase in the frequency of missing days. Results from the present study which prospectively addressed the role of in-center short daily hemodialysis in the management of ESRD are encouraging. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381946     DOI: 10.1159/000065280

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  6 in total

1.  Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients.

Authors:  Eric D Weinhandl; Jiannong Liu; David T Gilbertson; Thomas J Arneson; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

2.  Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials.

Authors:  Peter Kotanko; Amit X Garg; Tom Depner; Andreas Pierratos; Christopher T Chan; Nathan W Levin; Tom Greene; Brett Larive; Gerald J Beck; Jennifer Gassman; Alan S Kliger; John B Stokes
Journal:  Hemodial Int       Date:  2015-01-05       Impact factor: 1.812

3.  Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis.

Authors:  Paweena Susantitaphong; Ioannis Koulouridis; Ethan M Balk; Nicolaos E Madias; Bertrand L Jaber
Journal:  Am J Kidney Dis       Date:  2012-02-25       Impact factor: 8.860

4.  Effects of modality change on health-related quality of life.

Authors:  Patricia Painter; Joanne B Krasnoff; Michael Kuskowski; Lynda Frassetto; Kirsten Johansen
Journal:  Hemodial Int       Date:  2012-03-13       Impact factor: 1.812

5.  Patient's response to a simple question on recovery after hemodialysis session strongly associated with scores of comprehensive tools for quality of life and depression symptoms.

Authors:  Gildete Barreto Lopes; Luciana Ferreira Silva; Gustavo Behrens Pinto; Luiz Fernando Catto; Marcia Tereza Silva Martins; Margarida Maria Dantas Dutra; Antonio Alberto Lopes
Journal:  Qual Life Res       Date:  2014-03-14       Impact factor: 4.147

Review 6.  Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review.

Authors:  Tonci Brkovic; Eliana Burilovic; Livia Puljak
Journal:  Patient Prefer Adherence       Date:  2016-06-23       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.